DETROIT--(BUSINESS WIRE)--Asterand Bioscience is pleased to announce that is has been awarded a five-year, $6.5M contract from the National Institutes of Health (NIH) to provide oncology specimens with associated clinical data to the Clinical Proteomic Tumor Analysis Consortium (CPTAC). Asterand Bioscience has been working with the NIH since 2010 and has provided over 1,500 unique tumor specimens with over 2,500 individual clinical data sets to both The Cancer Genome Atlas (TCGA) Project and CPTAC.
Michael Button, Asterand Bio’s Principal Investigator for both the TCGA and CPTAC project says, “The TCGA and CPTAC projects are creating comprehensive new data sets about the nature of cancer and making them available to researchers globally. The aim is to greatly accelerate the cure for cancer. We are delighted that the NIH recognizes our ability to provide high quality and well annotated tissues with matching biofluids and has elected to extend our partnership.”
“We are delighted to support the NIH in its need for high quality, well annotated oncology tissues,” adds Peter Ferrigno Chief Commercial Office of Asterand Bioscience. “We are confident that the initiatives of the NIH will strengthen the research communities’ ability to find the cures for the cancers that invade us.”
About Asterand Bioscience
Asterand Bioscience is the leading global provider of high quality, well characterized human tissue and human tissue-based research solutions to drug discovery scientists. Our mission is to provide human-based solutions to accelerate the identification and validation of drug targets and enhance the selection of drug candidates with increased likelihood of clinical success.
Asterand Bioscience has a well-established human tissue heritage, having been formed in 2006 through the merger of Asterand (founded 2000), a human tissue biorepository and Pharmagene (founded 1996) a human tissue-based drug discovery company. With this background and capability in human tissue procurement, characterization and research tools, Asterand Bioscience is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical, biotechnology and diagnostic companies, as well as academia. From our offices in Detroit, MI and Royston, U.K. our employees are focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and drug safety.